You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK)擬發行7.5億歐元零息可轉債
格隆匯 01-23 08:18

格隆匯1月23日丨中國生物製藥(01177.HK)公佈,建議發行7.5億歐元於2025年到期的零息可轉換債券。

公告顯示,如果債券全部按每股股份的初步換股價19.09港元進行轉換、並且不再發行其他股份,債券將轉換成約3.38億股股份,約佔公司截至公告日已發行股本的2.69%,以及約佔公司在債券全部轉換下發行轉換股份後的已發行股本的2.62%。

據悉,預計債券所籌資金淨額約為7.42億歐元,對照初步換股價,每股轉換股份的發行價格淨額約為18.88港元。就債券發行所籌資金淨額集團擬用於研發開支、建設生產設施、銷售及營銷及一般企業用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account